[PREVIEW] Why European patients still can’t access 100 new drugs ?

Épisode de Pharma Minds par Nathalie Lahitte · 26 octobre 2025 · 2 min

Hundreds of breakthrough treatments are transforming patients’ lives in the US — but still aren’t available in Europe.

In this short extract, Pierre-Henri Belin, the Co-Founder and CEO of Xcube.Bio, reveals the shocking scale of this innovation gap… and why it’s growing.

The full episode drops tomorrow on Pharma minds — don’t miss it!

What you will learn in the full episode of tomorrow :

◾️ The alarming gap between the United States and Europe — with more than 100 new drugs available in the US but still not accessible to European patients.

◾️ Why this gap exists, from fragmented regulatory systems to national-level decision-making and the lack of early collaboration between key actors.

◾️ The consequences for patients, innovation, and the competitiveness of Europe’s healthcare ecosystem.

◾️ Pierre-Henri’s proposed model, built on transparency, collaboration, and shared responsibility — connecting innovators, regulators, and patients earlier in the process.

◾️ A message of hope, showing that Europe can reinvent its system without sacrificing safety or trust, but only if we act collectively and decisively.

A clear, concrete, and inspiring episode that sheds light on how Europe can regain its leadership in healthcare innovation.

See you tomorrow!

---

🎧 New here? To get a quick overview of the episodes, download “25 Tips for Purposeful Leadership”, a guide inspired by the best advice shared by my guests.

🤝 Want to connect or talk about your current challenges? Let’s connect on LinkedIn.

📩 Curious to dive deeper into the major shifts in the pharma and healthcare ecosystem? Subscribe to the Pharma Minds newsletter.

Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Autres épisodes de « Pharma Minds »

• #53 - Libérer du temps soignant : le pari d'un ingénieur à la Clinique Pasteur 19 octobre 2026
• [EXTRAIT] « On a toujours fait comme ça » : comment faire accepter le changement ? avec Loïc Lagarde 18 octobre 2026
• "Europe's Access Dilemma" (BONUS) - The Innovation Wave? Europe’s Payers Aren’t Convinced 12 octobre 2026
• "Europe's Access Dilemma" (5/5) - "Germany has a target on its back" What will Europe give up? 5 octobre 2026
• "Europe's Access Dilemma" (4/5) - Pharma Innovation: Your 8-Year Competitive Window Is Now Just 3 28 septembre 2026
• "Europe's Access Dilemma" (3/5) - MFN Is Already Changing Pharma Launch Strategy. Here’s How to Prepare. 21 septembre 2026
• "Europe's Access Dilemma" (2/5) - Europe Can't Pay More For Innovation: The Case For Co-developing With Asia 14 septembre 2026
• "Europe's Access Dilemma" (1/5) - Europe Is Losing Access to New Medicines. Here’s Why. 7 septembre 2026
• [Insights] Produits frontières : transformer la réglementation en avantage stratégique 2 septembre 2026
• "Executing differently takes courage" (5/5) - From managing global subsidiaries to walking the talk : when execution becomes personal 17 août 2026
• "Executing differently takes courage" (4/5) - Biotech survival and resource allocation : why execution is about choosing what not to do 10 août 2026
• "Executing differently takes courage" (3/5) - Trusting the ground : navigating volatility, growth and partnerships across the EEMEA zone 3 août 2026
• "Executing differently takes courage" (2/5) - The Chinese pharma ecosystem : balancing systemic scale and constant reinvention 27 juillet 2026
• "Executing differently takes courage" (1/5) Transforming Vidal : how a 20-year vision turned a paper book into digital infrastructure 20 juillet 2026
• [Insights] Groupements de pharmacies : ce qu’il faut retenir du rapport IGF-IGAS, avec Hugues Villey Desmeserets 8 juillet 2026

Tous les épisodes de Pharma Minds · Plus de podcasts Business